The UCLA Vine Street Clinic served as one of the study sites for the HPTN 083 trial, a study that sought to compare the efficacy of cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention. Data obtained from this and other studies helped inform the U.S. Food and Drug Administration (FDA)’s approval of long-acting cabotegravir (CAB-LA) injections for the prevention of HIV. “Results of this NIAD/NIH sponsored and co-funded study showed that CAB-LA injected once every eight weeks was superior to daily oral TDF/FTC for HIV prevention among cisgender men and transgender women who have sex with men (HPTN 083) and cisgender women (HPTN 084). Both studies also demonstrated that CAB-LA was well-tolerated, offering a new and important pre-exposure prophylaxis (PrEP) option for individuals at risk for HIV infection.” The protocol chair for HPTN 083 is Dr. Raphael Landovitz, long-time CBAM colleague and Co-Director of the Center for HIV Identification, Prevention and Treatment Services.

 

To read the full press release and learn more about the HPTN 083 study, click here | HPTN 083

About

CBAM is a multidisciplinary center that seeks to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities. As part of the UCLA Department of Family Medicine, CBAM works at the intersection of academia and community with a focus on treating addictions and preventing the spread of HIV.

© The UCLA Center for Behavioral & Addiction Medicine (CBAM). All Rights Reserved.